These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16959607)

  • 1. Mutant p53 gain of function: the NF-Y connection.
    Peart MJ; Prives C
    Cancer Cell; 2006 Sep; 10(3):173-4. PubMed ID: 16959607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation.
    Di Agostino S; Strano S; Emiliozzi V; Zerbini V; Mottolese M; Sacchi A; Blandino G; Piaggio G
    Cancer Cell; 2006 Sep; 10(3):191-202. PubMed ID: 16959611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53-mediated downregulation of H ferritin promoter transcriptional efficiency via NF-Y.
    Faniello MC; Di Sanzo M; Quaresima B; Baudi F; Di Caro V; Cuda G; Morrone G; Del Sal G; Spinelli G; Venuta S; Costanzo F
    Int J Biochem Cell Biol; 2008; 40(10):2110-9. PubMed ID: 18372207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 is a NF-Y- and p21-independent, Sp1-dependent repressor of cyclin B1 transcription.
    Innocente SA; Lee JM
    FEBS Lett; 2005 Feb; 579(5):1001-7. PubMed ID: 15710382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcription repression of a CCAAT-binding transcription factor CBF/HSP70 by p53.
    Chae HD; Yun J; Shin DY
    Exp Mol Med; 2005 Oct; 37(5):488-91. PubMed ID: 16264274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional activities of mutant p53: when mutations are more than a loss.
    Kim E; Deppert W
    J Cell Biochem; 2004 Nov; 93(5):878-86. PubMed ID: 15449312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant p53: an oncogenic transcription factor.
    Strano S; Dell'Orso S; Di Agostino S; Fontemaggi G; Sacchi A; Blandino G
    Oncogene; 2007 Apr; 26(15):2212-9. PubMed ID: 17401430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of mutant p53 with DNA: guilt by association.
    Kim E; Deppert W
    Oncogene; 2007 Apr; 26(15):2185-90. PubMed ID: 17401427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A balance between NF-Y and p53 governs the pro- and anti-apoptotic transcriptional response.
    Benatti P; Basile V; Merico D; Fantoni LI; Tagliafico E; Imbriano C
    Nucleic Acids Res; 2008 Mar; 36(5):1415-28. PubMed ID: 18187512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NF-Y/p53 liaison: well beyond repression.
    Imbriano C; Gnesutta N; Mantovani R
    Biochim Biophys Acta; 2012 Apr; 1825(2):131-9. PubMed ID: 22138487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of P-glycoprotein expression by low-dose fractionated radiation results from loss of nuclear factor-kappaB and NF-Y activation in oral carcinoma cells.
    Shareef MM; Brown B; Shajahan S; Sathishkumar S; Arnold SM; Mohiuddin M; Ahmed MM; Spring PM
    Mol Cancer Res; 2008 Jan; 6(1):89-98. PubMed ID: 18234965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters.
    Imbriano C; Gurtner A; Cocchiarella F; Di Agostino S; Basile V; Gostissa M; Dobbelstein M; Del Sal G; Piaggio G; Mantovani R
    Mol Cell Biol; 2005 May; 25(9):3737-51. PubMed ID: 15831478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimpanzee, orangutan, mouse, and human cell cycle promoters exempt CCAAT boxes and CHR elements from interspecies differences.
    Müller GA; Heissig F; Engeland K
    Mol Biol Evol; 2007 Mar; 24(3):814-26. PubMed ID: 17205977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcription regulation by mutant p53.
    Weisz L; Oren M; Rotter V
    Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73.
    Liu K; Ling S; Lin WC
    Mol Cell Biol; 2011 Nov; 31(22):4464-81. PubMed ID: 21930790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53: "gain of function" through perturbation of nuclear structure and function?
    Deppert W; Göhler T; Koga H; Kim E
    J Cell Biochem Suppl; 2000; Suppl 35():115-22. PubMed ID: 11389540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual transcriptional control of claudin-11 via an overlapping GATA/NF-Y motif: positive regulation through the interaction of GATA, NF-YA, and CREB and negative regulation through the interaction of Smad, HDAC1, and mSin3A.
    Lui WY; Wong EW; Guan Y; Lee WM
    J Cell Physiol; 2007 Jun; 211(3):638-48. PubMed ID: 17226765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
    Brazda V; Muller P; Brozkova K; Vojtesek B
    Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage.
    Kawamata H; Omotehara F; Nakashiro K; Uchida D; Shinagawa Y; Tachibana M; Imai Y; Fujimori T
    Int J Oncol; 2007 May; 30(5):1089-97. PubMed ID: 17390010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.